U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H4NO2.Cu
Molecular Weight 211.663
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC GLYCINATE

SMILES

[Cu++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=VVYPIVJZLVJPGU-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Cu/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H4NO2
Molecular Weight 74.0587
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/16971307https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttp://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper sulfate is a dark blue crystalline solid with a faint odor of ammonia. The primary hazard is the threat to the environment. Immediate steps should be taken to limit its spread to the environment. Used as a pesticide and fungicide, to print fabrics (especially in calico finishing), and to make other copper compounds.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
The effect of various fluoride compounds on the development of experimental root surface caries in hamsters.
1995 Dec
Direct catalytic aldol-type reactions using RCH2CN.
2003 Aug 21
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.
2011 Oct 15
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
SILAC-based quantitative proteomic analysis of human lung cell response to copper oxide nanoparticles.
2014
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts.
2014
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.
2014 Jul
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.
2015 Jun
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Roles of Copper-Binding Proteins in Breast Cancer.
2017 Apr 20
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.
2017 May
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:45 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:45 GMT 2025
Record UNII
68VAV8QID7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC GLYCINATE
GREEN BOOK  
Common Name English
COPPER GLYCINATE
INCI   WHO-DD  
INCI  
Preferred Name English
COPPER(II) GLYCINATE
Systematic Name English
BIS(GLYCINATO-N,O)COPPER
Common Name English
Copper glycinate [WHO-DD]
Common Name English
CUPRIC BISGLYCINATE
MI  
Common Name English
CUPRIC BISGLYCINATE [MI]
Common Name English
CUPRIC GLYCINATE [GREEN BOOK]
Common Name English
NSC-162736
Code English
COPPER(II) BISGLYCINATE
Systematic Name English
Classification Tree Code System Code
CFR 21 CFR 522.518
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
NCI_THESAURUS C802
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
Code System Code Type Description
WIKIPEDIA
Copper(II) glycinate
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
CAS
32817-15-5
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
ALTERNATIVE
CAS
5789-40-2
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
SUPERSEDED
EVMPD
SUB13502MIG
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
SMS_ID
100000079503
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
RXCUI
1428217
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY RxNorm
CAS
13479-54-4
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
NSC
162736
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
EPA CompTox
DTXSID40893690
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
DAILYMED
68VAV8QID7
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
DRUG BANK
DB11509
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
ECHA (EC/EINECS)
236-783-2
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
PUBCHEM
3032611
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
NCI_THESAURUS
C83639
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
ECHA (EC/EINECS)
251-238-9
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
ALTERNATIVE
MERCK INDEX
m3887
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY Merck Index
CAS
142-51-8
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
SUPERSEDED
FDA UNII
68VAV8QID7
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
MESH
C018493
Created by admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY